Repligen to Present at Jefferies 2019 Healthcare Conference
June 04 2019 - 10:03AM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that Jon K.
Snodgres, Chief Financial Officer, will present at the Jefferies
2019 Global Healthcare Conference on Thursday, June 6 at 8:30 a.m.
EDT.
A live audio webcast of the presentation will be
accessible through the Investor Events section of the Company’s
website, and will be available for replay for a limited period of
time following the conference event.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing
company that develops and commercializes highly innovative products
that deliver cost and process efficiencies to biological drug
manufacturers worldwide.
Our portfolio includes filtration products
(including XCell™ ATF, TangenX™ SIUS™ TFF and Spectrum KrosFlo™ TFF
filters and systems), chromatography products (OPUS® pre-packed
columns, chromatography resins, ELISA kits), process analytics
products (SoloVPE and FlowVPE instruments and systems) and protein
products (Protein A affinity ligands including NGL Impact®-A, cell
culture growth factors).
Our XCell™ ATF Systems, available in stainless
steel and single-use configurations, are used in perfusion
processes to continuously concentrate cells and increase product
yield from a bioreactor. Single-use SIUS™ TFF cassettes and
hardware are used for biologic drug concentration in downstream
filtration processes. KrosFlo™ TFF cartridges and systems are used
in both upstream and downstream filtration processes. Our
innovative line of OPUS® chromatography columns, used in
bench-scale through commercial-scale biologics purification, are
delivered pre-packed to our customers with their choice of affinity
resin. Our process analytics products, which are used in both
upstream and downstream applications, enable at-line and in-line
protein concentration measurement in filtration, chromatography and
fill-finish operations. The Protein A ligands and growth factor
products that we produce are essential components of Protein A
affinity resins used in biologics purification, and cell culture
media used to accelerate cell growth in a bioreactor.
Repligen’s corporate headquarters are in Waltham,
MA (USA), with additional administrative and manufacturing
operations in Marlborough, MA; Rancho Dominguez, CA; Lund, Sweden;
Breda, The Netherlands and Ravensburg, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Source: Repligen Corporation Sondra Newman Global Head of
Investor Relations(781) 419-1881 snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024